First patient treated with RayStation reirradiation tools in Leeds

Glycorex Transplantation is broadening its strategy to develop standardized, universal blood products for civilian healthcare, emergency preparedness, and military medicine. The work will be carried out through its new subsidiary, Glycorex Universal Blood Products (UBP).

Swedish SenzaGen has agreed to acquire Alcyomics, a UK company that tests drug candidates for immune-related side effects without using animals. The initial price is approximately SEK 28 million, and the deal takes SenzaGen into safety testing of biological drugs such as antibodies and T-cell engagers.

Uppsala-based diagnostics company Gradientech has launched QuickMIC GN02, a new panel for its rapid antibiotic susceptibility testing (AST) system that gives results for hard-to-treat Gram-negative bacteria in 3 hours and 14 minutes. The panel is CE marked under the EU's IVDR.

Norwegian medtech company Medistim reported record third-quarter revenue of NOK 210.0 million, up 25.9% from NOK 166.8 million a year earlier. Operating profit rose 55.7% to NOK 63.1 million, and the board decided on the company’s first quarterly dividend, NOK 2.50 per share.

Episurf Medical has signed a letter of intent with Canada’s Oligo Medic for the possible sale of its medical technology business, as the Swedish company shifts its focus to real estate.

Swedish medtech company Getinge raised its adjusted EBITA margin to 15.1% in the third quarter of 2026, from 13.1% a year earlier, while organic sales grew 2.1%. The company kept its forecast of 3–5% organic sales growth for the full year.

Spago Nanomedical’s Board of Directors has resolved to apply for delisting from the Nasdaq First North Growth Market, subject to approval at an extraordinary general meeting on November 19, 2026. The goal is to make it easier to finance the next phase of Tumorad’s development with long-term specialist investors.